RxDoctor Payments Data

Christine Pontarelli, APRN

Nurse Practitioner · Warrenville, ILNPI 1508401175

Payments from drug & device makers

$2,572in general payments, 2019–2025

Across 91 payments — averaging $28.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$331
  • Astellas Pharma US Inc$248
  • Novartis$158
  • Daiichi Sankyo Inc.$153
  • Incyte Corporation$152
  • E.r. Squibb & Sons, L.L.C.$135
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,39893%
  • Education$1747%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,572 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$34,944
Medicare patients
114
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib24$359,973
TukysaTucatinib13$267,855
IbrancePalbociclib16$258,880
ImbruvicaIbrutinib15$243,592
EliquisApixaban67$52,275
XareltoRivaroxaban28$26,166
Exemestane31$4,299
Raloxifene Hcl77$2,951
Tamoxifen Citrate77$2,031
Anastrozole76$1,501
Letrozole60$1,345
Gabapentin35$519
Warfarin Sodium49$489
Dexamethasone13$388
Prochlorperazine Maleate36$339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$66$359,97324 claims
PfizerIbrance, Eliquis$70$311,15583 claims
Seagen Inc.Tukysa$125$267,85513 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$16$243,59215 claims
Johnson & JohnsonXarelto$129$26,16628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Warrenville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →